Cargando…
Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
Rituximab is a pioneering anti-CD20 monoclonal antibody that became the first-line drug used in immunotherapy of B-cell malignancies over the last twenty years. Rituximab activates the complement system in vitro, but there is an ongoing debate on the exact role of this effector mechanism in therapeu...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710700/ https://www.ncbi.nlm.nih.gov/pubmed/33329558 http://dx.doi.org/10.3389/fimmu.2020.584509 |